Together, the companies will produce Kaida’s KAD101 to treat uterine cancer.

Northway Biotech, an end-to-end CDMO, and Kaida BioPharma, an early-stage pharma company, have entered into a manufacturing agreement to produce Kaida’s KAD101.

Per the agreement, Northway Biotech will leverage its expertise to develop a robust manufacturing process for KAD101. 

This involves developing analytical methods, optimizing formulation, development, and scaling up of the production process, and manufacturing a cGMP drug substance batch for clinical studies.

KAD101 is a novel biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy, initially targeting ovarian cancer. 

The original biologic G129R demonstrated encouraging results in a human clinical study, with all patients showing tumor reduction on the low-dose cohort with a clean safety profile as a daily injectable. 

Kaida has transformed G129R into a bi-weekly injectable (KAD101) and continues to progress the development towards the launch of a Phase 1 study. This study is expected to start Q4 2026/Q1 2027. 

Additionally, Kaida is advancing KAD102, an enhanced pure antagonist of KAD101, to treat uterine cancer.

Craig Pierson, Founder and Chairman of Kaida BioPharma, commented: “We look forward to working closely with the Northway Biotech team to advance our lead product candidate, KAD101, and progress towards providing targeted anti-cancer therapies to address hormone-driven cancers affecting women.”